European benchmarking of lung cancer care

Wilking, N; Högberg, D.; Jonsson, Bengt‐Gunnar

doi:10.1200/jco.2008.26.15_suppl.17535

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In France, the National Institute of Cancer estimated the direct medical cost of cancer to be € 11 billion in 2004 [ 9 ], rising to € 15 billion in 2014, of which anticancer drugs accounted for 22% [ 1 ]. In the disease-related group (DRG) payment scheme in French hospitals, the acquisition cost of most drugs is included in the unit cost of hospitalisation.…”

Section: Introductionmentioning

confidence: 99%

Access to innovative drugs for metastatic lung cancer treatment in a French nationwide cohort: the TERRITOIRE study

et al. 2018

View full text Add to dashboard Cite

BackgroundTerritorial differences in the access to innovative anticancer drugs have been reported from many countries. The objectives of this study were to evaluate access to innovative treatments for metastatic lung cancer in France, and to assess whether socioeconomic indicators were predictors of access at the level of the municipality of residence.MethodsAll incident cases of metastatic lung cancer hospitalised for a chemotherapy in public hospitals in 2011 were identified from the French National Hospital discharge database. Information on prescription of innovative drugs from an associated database (FICHCOMP) was crossed with the population density of the municipality and a social deprivation index based on national census data.ResultsOverall, 21,974 incident cases of metastatic lung cancer were identified, all of whom were followed for 2 years. Of the 11,486 analysable patients receiving chemotherapy in the public sector, 6959 were treated with a FICHCOMP drug at least once, principally pemetrexed. In multivariate analysis, prescription of FICHCOMP drugs was less frequent in patients ≥66 years compared to those ≤55 years (odds ratio: 0.49 [0.44–0.55]), in men compared to women (0.86 [0.79–0.94]) and in patients with renal insufficiency (0.55 [0.41–0.73]) and other comorbidities. Prescription rates were also associated with social deprivation, being lowest in the most deprived municipalities compared to the most privileged municipalities (odds ratio: 0.82 [0.72–0.92]). No association was observed between the population density of the municipality and access to innovative drugs.ConclusionAlthough access to innovative medication in France seems to be relatively equitable, social deprivation is associated with poorer access. The reasons for this need to be investigated and addressed.

show abstract

Section: Introductionmentioning

confidence: 99%